Iron in liver diseases other than hemochromatosis

Seminars in Liver Disease

Volumn 16, Issue 1, 1996, Pages 65-82

  Bonkovsky, Herbert L ^a   Banner, Barbara F ^a   Lambrecht, Richard W ^a   Rubin, Richard B ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ALANINE AMINOTRANSFERASE; ALCOHOL; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; CERULOPLASMIN; CYANOCOBALAMIN; CYTOCHROME P450; FERRITIN; FOLIC ACID; HEME; HLA ANTIGEN; INTERFERON; INTERLEUKIN 1; IRON; IRON BINDING PROTEIN; LIPID; MALONALDEHYDE; MESSENGER RNA; ORAL CONTRACEPTIVE AGENT; OXYGEN RADICAL; PORPHYRIN; PROCOLLAGEN; PYRROLIZIDINE; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; UROPORPHYRIN; UROPORPHYRINOGEN DECARBOXYLASE;

ALCOHOL LIVER DISEASE; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; HEMOCHROMATOSIS; HEPATITIS; HUMAN; IRON OVERLOAD; KUPFFER CELL; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHLEBOTOMY; PORPHYRIA; PORPHYRIA CUTANEA TARDA; PORTOCAVAL SHUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDEROSIS;

EID: 0029873729     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007220     Document Type: Review

References (135)

1. Powell LW: Normal human iron storage and its relation to ethanol consumption. Aust Ann Med 15:110-5, 1966.
2. Barry M: Iron and chronic liver disease. J Royal Coll Phys Lond 8:52-62, 1973.
3. Bonkovsky HL, Slaker DP, Bills LB. Wolf DC: Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. Gastroenterology 99:1080-91, 1990.
4. Lundvall O, Weinfeld A, Lundin P: Iron stores in alcohol abusers. I. Liver iron. Acta Med Scand 185:259-69, 1969.
5. Lundvall O, Weinfeld A, Lundin P: Iron stores in alcohol abusers. II. As measured by the desferrioxamine tests. Acta Med Scand 185:271-7, 1969.
6. Gordeuk V, Mukiibi J, Hasstedt SJ, et al: Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 326:95-100, 1992.
7. Moyo VM, Gome ZAR, Saungwerre T, Gordeuk VR: Evidence for genetic transmission in African iron overload. Abstract presented at the Fifth Biennial Conference of the International Association for the Study of Disorders of Iron Metabolism; Boston, MA, April, 1995.
8. Chapman RW, Morgan MY, Bell R, Sherlock S: Hepatic iron uptake in alcoholic liver disease. Gastroenterology 84:143-7, 1983.
9. Stibler H, Borg S: Evidence of reduced sialic acid content in serum transferrin in male alcoholics. Alcohol Clin Exp Res 55:545-9, 1981.
10. Ashwell G, Morell AG: The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 41:99-128, 1974.
11. Thorstensen K, Romslo I: Uptake of iron from transferrin by isolated rat hepatocytes. A redox-mediated plasma membrane process. J Biol Chem 263:8844-50, 1988.
12. Tsukamoto H, Home W, Kamimura S, et al: Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 96:620-30, 1995.
13. Shaw S, Jayatilleke E, Lieber CS: Lipid peroxidation as a mechanism of alcoholic liver injury: role of iron mobilization and microsomal induction. Alcohol 5:135-40, 1988.
14. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 107:1103-9, 1994.
15. Hocking MP, Duerson MC, Alexander RW, Woodward ER: Late hepatic histopathology after jejunoileal bypass for morbid obesity. Am J Surg 141:159-63, 1981.
16. Hamilton DL, Vest TK, Brown BS, et al: Liver injury with alcoholic like hyaline after gastroplasty for morbid obesity. Gastroenterology 85:722-6, 1983.
17. Capron J-P, Delamarre J, Dupas J-L, et al: Fasting in obesity. Another cause of liver injury with alcoholic hyaline? Dig Dis Sci 27:265-8, 1982.
18. Motrand R, Mortaji A, Loreal O, et al: Unexplained isolated hyperferritinemia: a new entity of non-HLA-A3 linked and over-weight-related iron overload? Hepatology 20:322A, 1994.
19. Bloomer JR, Straka JG, Rank JM: The Porphyrias. In: Schiff L, Schiff ER (eds) Diseases of the liver. 7th ed. Philadelphia, J.B. Lippincott Company, 1993. pp 1438-64.
20. Schmid R: Cutaneous porphyria due to intoxication. N Engl J Med 263:397-8, 1960.
21. Lambrecht RW, Sinclair PR, Bement WJ, Sinclair JF: Uroporphyrin accumulation in cultured chick embryo hepatocytes: comparison of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 3,4,3′,4′-tetrachlorobiphenyl. Toxicol Appl Pharmacol 96: 507-16, 1988.
22. Goldstein JA, Hickman P, Bergman H, Vos JG: Hepatic porphyria induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the mouse. Res Commun Chem Pathol Pharmacol 6:919-28, 1973.
23. Epstein JH, Redeker AG: Porphyria cutanea tarda. A study of the effect of phlebotomy. N Engl J Med 279:1301-4, 1968.
24. Smith AG, Carthew P, Francis JE, Ingebrigtsen K: Influence of iron on the induction of hepatic tumors and porphyria by octachlorostyrene in C57BL/10ScSn mice. Cancer Letters 81:145-50, 1994.
25. Bloomer JR, Bonkovsky HL: The porphyrias. Disease-a-Month XXXV:1-49, 1989.
26. Kordac V: Frequency of occurrence of hepatocellular carcinoma in patients with porphyria cutanea tarda in long term follow-up. Neoplasma 19:135, 1972.
27. Elder GH, Urquhart AJ, De Salamanca RE, et al: Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet 1:229-232, 1985.
28. Garey JR, Hansen JL, Harrison LM, et al: A point mutation in the coding region of uroporphyrinogen decarboxylase associated with familial porphyria cutanea tarda. Blood 73:892-5, 1989.
29. Romana M, Grandchamp B, Dubart A, et al: Identification of a new mutation responsible for hepatoerythropoietic porphyria. Eur J Clin Invest 21:225-9, 1991.
30. Piperno A, D'Alba R, Roffi L, et al: Hepatitis C virus infection in patients with idiopathic hemochromatosis (IH) and porphyria cutanea tarda (PCT). Arch Virol Suppl 4:215-6, 1992.
31. DeCastro M, Sanchez J, Herrera JF, et al: Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 17:551-7, 1993.
32. Lacour JP, Bodokh I, Castanet J, et al: Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol 128:121-3, 1993.
33. Stolzel U, Kostler E, Koszka C, et al: Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 21:1500-3, 1995.
34. Enriquez de Salamanca R. Rico R, Pena ML. et al: Patterns of porphyrin excretion in porphyria cutanea tarda under venesection treatment. Int J Biochem 12:861-8, 1980.
35. Rocchi E, Cassanelli M, Borghi A, et al: Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda. Dermatologica 182:27-31, 1991.
36. Rocchi E, Gilbertini P, Cassanelli M, et al: Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med 107:36-42, 1986.
37. Lundvall O: The effect of replenishment of iron stores after phlebotomy therapy in porphyria cutanea tarda. Acta Med Scand 189:51-63, 1971
38. Edwards CQ, Griffen LM, Goldgar DE, et al: HLA-linked hemochromatosis alleles in sporadic porphyria cutanea tarda. Gastroenterology 97:972-81, 1989.
39. Courtney KD: Hexachlorobenzene (HCB): a review. Environ Res 20:225-66, 1979.
40. De Matteis F, Prior BE, Rimington C: Nervous and biochemical disturbances following hexachlorobenzene intoxication. Nature 191:363-5, 1961.
41. Smith AG, Carthew P, Francis JE, et al: Enhancement by iron of hepatic neoplasia in rats caused by hexachlorobenzene. Carcinogenesis 14:1381-7, 1993.
42. Tschudy DP, Bonkovsky HL: Experimental porphyria. Fed Proc 31:147-59, 1972.
43. Sinclair PR, Bement WJ, Lambrecht RW, et al: Chlorinated biphenyls induce cytochrome P4501A2 and uroporphyrin accumulation in cultures of mouse hepatocytes. Arch Biochem Biophys 281:225-32, 1990.
44. Lambrecht RW, Sinclair PR, Bement WJ, et al: Hepatic uroporphyrin accumulation and uroporphyrinogen decarboxylase activity in cultured chick-embryo hepatocytes and Japanese quail (Coturnix coturnix japonica) and mice treated with polyhalogenated aromatic compounds. Biochem J 253:131-8, 1988.
45. Bonkovsky HL: Mechanism of iron potentiation of hepatic uroporphyria: Studies in cultured chick embryo liver cells. Hepatology 10:354-64, 1989.
46. Sinclair P, Lambrecht R, Sinclair J: Evidence for cytochrome P450-mediated oxidation of uroporphyrinogen by cell-free liver extracts from chick embryos treated with 3-methylcholanthrene. Biochem Biophys Res Commun 146:1324-9, 1987.
47. Smith AG, Francis JE, Dinsdale D, et al: Hepatocarcinogenicity of hexachlorobenzene in rats and the sex difference in hepatic iron status and development of porphyria. Carcinogenesis 6:631-6, 1985.
48. Smith AG, Francis JE: Genetic variation of iron-induced uroporphyria in mice. Biochem J 291:29-35, 1993.
49. Gabis KK, Gildemeister OS, Donohue S, et al: LMH cells, a new model system for study of heme and iron metabolism. Abstract presented at the Fifth Biennial Conference of the International Association for the Study of Disorders of Iron Metabolism; Boston, MA, April, 1995.
50. Siersema PD, Rademakers LHPM, Cleton MI, et al: The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: the role of iron. J Hepatol 23:259-67, 1995.
51. Mukerji SK, Pimstone NR: In vitro studies of the mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity by ferrous iron under anaerobic conditions. Arch Biochem Biophys 244:619-29, 1986.
52. De Verneuil H, Sassa S, Kappas A: Purification and properties of uroporphyrinogen decarboxylase from human erythrocytes. A single enzyme catalyzing the four sequential decarboxylations of uroporphyrinogens I and III. J Biol Chem 258-2454-60, 1983.
53. Cantoni L, Dal Fiume D, Rizzardini M, Ruggieri R: In vitro inhibitory effect on porphyrinogen carboxylase of liver extracts from TCDD treated mice. Toxicol Lett 20:211-7, 1984.
54. Smith AG, Francis JE: Chemically induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload. Biochem J 246:221-6, 1987.
55. Van Gelder W, Siersema PD, Voogd A, et al: The effect of desferrioxamine on iron metabolism and lipid peroxidation in hepatocytes of C57BL/10 mice in experimental uroporphyria Biochem Pharmacol 2:221-8, 1993.
56. Stein JA, Tschudy DP, Corcoran LP, Collins A: Delta-aminolevulinic acid synthetase. Synergistic effect of chelated iron on induction. J Biol Chem 245:2213-8, 1970.
57. Bonkovsky HL, Sinclair PR, Sinclair JF: Hepatic heme metabolism and its control. Yale J Biol Med 52:13-37, 1979.
58. Shedlofsky SI, Bonkovsky HL, Sinclair PR, et al: Iron loading of cultured hepatocytes: effect of iron on 5-aminolevulinate synthase is independent of lipid peroxidation. Biochem J 212:321-30, 1983.
59. Cable EE, Greene Y, Healey JF, et al: Mechanism of the synergistic induction of hepatic heme oxygenase by glutethimide and iron: studies in cultured chick embryo liver cells. Biochem Biophys Res Commun 168:176-81, 1990.
60. Cable EE, Healey JF, Greene Y, et al: Mechanisms of the syn-ergistic induction of delta-aminolevulinate synthase by glutethimide and iron: relationship to the synergistic induction of heme oxygenase. Biochim Biophys Acta 1080:245-51, 1991.
61. Lustbader ED, Hann HW, Blumberg BS: Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 220:423-5, 1983.
62. Dinarello CA: Interleukin-1. Rev Infect Dis 6:51-95, 1984.
63. Crichton RR, Ward RJ, Iron Metabolism - new perspectives in view. Biochemistry 31:11254-64, 1992.
64. Hasegawa K, Motsuchi W, Tanaka S, et al: Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J Med Sci Biol 47:73-85, 1994.
65. Dai Y, Gold B, Vishwanatha JK, et al: Mimosine inhibits viral DNA synthesis through ribonucleotide reductase. Virology 205:210-6, 1994.
66. Karupiah G, Harris N: Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites. J Exp Med 181:2171-9, 1995.
67. Bryan CF, Leech SH: The immunoregulatory nature of iron. Cell Immunol 75:71-9, 1983.
68. Rudd MJ, Good MF, Chapman DE, et al: Clonal analysis of the effect of iron on human cytotoxic and proliferating T lymphocytes. Immunol Cell Biol 68:317-24, 1990.
69. Munn CG, Markenson AL, Kapadia A, et al: Impaired T-cell mitogen responses in some patients with thalassemia intermedia. Thymus 3:119-28, 1981.
70. Hann HW, Stahlhut MW, Chung C: Inhibitory effect of isoferritins from tumor and non-tumor tissues on e-rosette formation. Lancet 1:43-6, 1984.
71. Nishiya K, Horwitz DA: Contrasting effects of lactoferrin on human lymphocyte and monocyte natural killer activity and antibody-dependent cell-mediated cytotoxicity. J Immunol 129:2519-24, 1982.
72. Good MR, Powell LW, Halliday JW: The effect of nontransferrin-bound iron on murine T lymphocyte subsets: analysis by clonal techniques. Clin Exp Immunol 70:164-72, 1987.
73. Bryan CF, Nishiya K, Pollack MS, et al: Differential inhibition of the MLR by iron: association with the HLA phenotype. Immunogenetics 12:129-40, 1981.
74. Waterlot Y, Cantinieaux B, Hariga-Muller C, et al: Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: the critical role of iron overload. Br Med J 291:501-4, 1985.
75. Cantinieauz B, Hariga C, Ferster A, et al: Neutrophil dysfunctions in thalassaemia major the role of cell iron overload. Eur J Hematol 39:28-34, 1987.
76. Hilgartner MW, Grady RW: Decreased natural killer activity in thalassemia major: a possible consequence of iron overload. J Immunol 136:1635-40.
77. Kaplan JS, Sarnaik S, Gitlin J, et al: Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 64:308-12, 1984.
78. Matzner Y, Hershko C, Polliack A, et al: Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol 42:345-53, 1979.
79. Wigginton JM: Reversal of ferritin-mediated immunosuppression by levamisole. a rationale for its application to management of the acquired immune deficiency syndrome. Med Hypotheses 44:85-8, 1995.
80. Mulvey MR, Fang H, Holmes CF, et al: The cellular U-particle, whose synthesis is induced by mengovirus infection, is homologous to apoferritin. Virology 198:81-1, 1994.
81. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, et al: Measurement of iron status in patients with chronic hepatitis. Gastroenterology 102:2108-13, 1992.
82. Van Thiel DH, Friedlander L, Fagiuoli S, et al: Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 20:410-5, 1994.
83. Olynyk JK, Reddy KR, Di Bisceglie AM, et al: Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic HCV. Gastroenterology 108:1104-9, 1995.
84. Barton AL, Banner BF, Cable EE, et al: Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 103:419-24, 1995.
85. Banner BF, Barton AL, Cable EE, et al: A detailed analysis of the Knodell score and hepatitis C. Mod Pathol 8:232-8, 1995.
86. Fargion S, Carazzone A, Molteni V, et al: Iron and response to interferon alpha in chronic hepatitis C. Hepatology 22:415A, 1995.
87. Bacon BR, Rebholz AE, Freid M, et al: Beneficial effect of iron-reduction therapy in patients with chronic hepatitis C who failed to respond to alpha interferon. Hepatology 18:150A, 1993.
88. Hayashi H, Takikawa T, Nishimura N, et al: Improvement of serum aminotransferases after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am I Gastroenterol 89:986-8, 1994.
89. Van Thiel DH, Friedlander L, Malloy P, et al: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with an without phlebotomy. Gastroenterology 106:A1002, 1994.
90. Fellows I, Steward M, Jeffcoate W, et al: Hepatocellular carcinoma in primary haemochromatosis in the absence of cirrhosis. Gut 29:1603-6, 1988.
91. Deugnier Y, Guyader D, Crantock L, et al: Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 104:228-34, 1993.
92. Turlin B, Juguet F, Moirand R, et al: Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 22:446-50, 1995.
93. Park C, Bacon B, Brittenham E, Tavill A: Pathology of dietary carbonyl iron overload. Lab Invest 57:555-63, 1987.
94. Wienberg E: Roles of iron in neoplasia: promotion, prevention and therapy. Biol Trace Elem Res 344:123-40, 1992.
95. Weinberg E: Association of iron with respiratory tract neoplasia. J Trace Elem Exp Med 6:117-23, 1993.
96. Nelson R, Davis F, Sutter E, et al: Body iron stores and risk of colonic neoplasia. J Natl Cancer Inst 78:136-43, 1977.
97. Bergeron R, Streiff R, Elliott G: Influence of iron on in vivo proliferation and lethality of L1210 cells. J Nutr 115:369-74, 1985.
98. Thompson H, Kennedy K, Witt M, Juzefyk J: Effect of dietary iron deficiency or excess on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis 12:111-4, 1991.
99. Fernandez-Pol J: Iron: possible cause of the G1 arrest induced in NRK cells by picolinic acid. Biochem Biophys Res Commun 78:136-43, 1977.
100. Hann H, Stahlhut M, Hann C: Effect of iron and deferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 11:566-9, 1990.
101. Hann H, Stahlhut M, Rubin R, Maddrey W: Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70:2051-6, 1992.
102. Goldfischer S, Grotsky HW, Chang CH, et al: Idiopathic neonatal iron storage involving the liver, pancreas, heart, and endocrine and exocrine glands. Hepatology 1:58-64, 1981.
103. Witzleben CL, Uri A: Perinatal hemochromatosis. Entity or end result? Hum Pathol 20:335-40, 1989.
104. Barnard JA, Manci E: Idiopathic neonatal iron-storage disease. Gastroenterology 101:1420-7, 1991.
105. Knisely AS: Neonatal hemochromatosis. Adv Pediatr 39:383-303, 1992.
106. Silver MM, Valberg LS, Cutz E, et al: Hepatic morphology and iron quantitation in perinatal hemochromatosis. Comparison with a large perinatal control population, including cases with chronic liver disease. Am J Pathol 143:1312-25, 1993.
107. Silver MM, Beverly DW, Valberg LS, et al: Perinatal he-mochromatosis. Clinical, morphologic and quantitative iron studies. Am J Pathol 128:538-54, 1987.
108. Blisand KS, Baron SA: Neonatal hemochromatosis. Hum Pathol 17:376-83, 1986.
109. McArdle HJ, Morgan EH: Transferrin and iron movements in the rat conceptus during gestation. J Reprod Fertil 66:529-36, 1982.
110. Knisely AS, Grady RW, Kramer EE, Jones RL: Cytoferrin, maternofetal iron transport and neonatal hemochromatosis. Am J Clin Pathol 92:755-9, 1989.
111. Knisely AS, Harford JB, Klausner RD, Taylor SR: Neonatal hemochromatosis. The regulation of transferrin-receptor and ferritin synthesis by iron in cultured fibroblastic-line cells. Am J Pathol 134:439-45, 1989.
112. Craven CM, Eldridge M, Kushner JP, et al: Tissue distribution and clearance kinetics of nontransferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc Natl Acad Sci USA 84:3457-61, 1987.
113. Schneider BL, Setchell KDR, Whitington PF, et al: Delta 4-3-oxosteroid 5β-reductase deficiency causing neonatal liver failure and hemochromatosis. J Pediatr 124:234-8, 1994.
114. Schoenlebe J, Buyon JP, Zitelli BJ, et al: Neonatal hemochromatosis associated with maternal autoantibodies against Ro/SSA and La/SS-B ribonucleoproteins. Am J Dis Child 147:1072-5, 1993.
115. Kershisnik MM, Knisely AS, Sun CCJ, et al: Cytomegalovirus infection, fetal liver disease, and neonatal hemochromatosis. Hum Pathol 23:1075-80, 1992.
116. Berger HM, Lindeman JHN, van Zoeren-Grobben D, et al: Iron overload, free radical damage, and rhesus haemolytic disease. Lancet 335:933-6, 1990.
117. Lasker MR, Eddleman K, Toor AH: Neonatal hepatitis and excessive hepatic iron deposition following intrauterine blood transfusion. Am J Perinatol 12:14-7, 1995.
118. Lee RG: Diagnostic liver pathology. St. Louis, C.V. Mosby, 1994. p 238.
119. Tuttle SG, Figueroa WG, Grossman MI: Development of hemochromatosis in patients with Laennec's cirrhosis. Am J Med 26:655-65, 1959.
120. Hearn GW: Development of diabetes mellitus after portacaval anastomosis. Br Med J 2:96-7, 1963.
121. Doberneck RC, Nunn DB, Johnson DC, et al: Iron metabolism after portacaval shunt in dogs. Arch Surg 87:741-3, 1963.
122. Conn HO: Portacaval anastomosis and hepatic hemosiderin deposition: a prospective, controlled investigation. Gastroenterology 62:61-72, 1972.
123. Doberneck RC, Fischer R, Smith D: Gastrojejnostomy inhibits postshunt siderosis. Surgery 78:334-8, 1975.
124. Monta H, Ikeda S, Yamamoto K, et al: Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 37:646-56, 1995.
125. Yoshida K, Furihata K, Takeda S, et al: A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nature Genetics 9:267-72, 1995.
126. Izumi N, Nouchi T, Enomoto N, et al: Association of response to interferon with hepatic iron content in patients with hepatitis C: relationship to genotypes of HCV. Gastroenterology 108:A1091, 1995.
127. Zein NN, Gross JB, Poterucha JJ, et al: Significance of serum iron, iron saturation, and ferritin in patients infected with different hepatitis C genotypes. Gastroenterology 108:A1208, 1995.
128. Clemente MG, Congia M, Lai ME, et al: Effect of iron overload on the response to recombinant interferon-alpha treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 125:123-8, 1994.
129. Girelli CM, Mirata C, Lengo E: Iron overload and response to alpha-interferon in chronic hepatitis C. Am J Gastroenterol 90:170, 1995.
130. Hayashi H, Takikawa T, Nishura N, et al: Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22:268-71, 1995.
131. Bayraktar Y, Koseoglu T, Kayhann B, et al: The use of desferrioxamine infusion to enhance the response rate to interferon alpha treatment of chronic viral hepatitis. Gastroenterology 108:A1031, 1995.
132. Kugelmas M, Lieberman BY, Carey WD: Deironization in chronic hepatitis C patients previously nonresponsive to interferon improves transaminases but not viral activity. Gastroenterology 108:A1104, 1995.
133. Han S-H, Fong T-L, Valinluck B, et al: Randomized controlled trial of the effect of iron depletion on aminotransferase levels, HCV RNA and response to interferon therapy in patients with chronic hepatitis C virus. Hepatology 22:180A, 1995.
134. Yano M, Kakumu S, Takikawa T, Nishimura N: Phlebotomy followed by α-interferon therapy in patients with chronic hepatitis C. Hepatology 22:119A, 1995.
135. Rubin RB, Barton AL, Banner BF, Bonkovsky HL: Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis 13:223-8, 1995.